From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma

Hussain, S. A., Birtle, A., Crabb, S., Huddart, R., Small, D., Summerhayes, M., Jones, R. and Protheroe, A. (2018) From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. European Urology Oncology, 1(6), pp. 486-500. (doi: 10.1016/j.euo.2018.05.011) (PMID:31158093)

[img]
Preview
Text
188461.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

1MB

Abstract

Context: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. Objective: To review the evidence from these trials and consider what it means for the use of these drugs in first-line and post-platinum settings in real-life clinical practice. Evidence acquisition: PubMed was searched for full reports of clinical trials of single-agent PD-1/PD-L1 inhibitors in advanced UC. Twelve publications were included. Evidence synthesis: Responses to PD-1/PD-L1 inhibitors appear to be durable but are only achieved in 17–26% of patients. These drugs offer different toxicity and efficacy profiles to standard chemotherapy regimens. This should be considered when choosing a treatment strategy for each patient. Conclusions: PD-1/PD-L1 inhibitors represent a major step forward in the management of advanced UC, although several questions remain regarding their optimal use in routine clinical practice. A validated predictive biomarker of response is yet to be defined, and this is perhaps the most significant unmet need for currently available drugs. Patient summary: We reviewed the results from clinical trials that investigated how well certain types of anticancer drugs called PD-1/PD-L1 inhibitors worked in patients with bladder cancer. We found that more research is required to identify (1) the factors that might predict which patients with bladder cancer will respond to PD-1/PD-L1 inhibitors and (2) the optimum duration of treatment with these drugs.

Item Type:Articles
Keywords:Atezolizumab, avelumab, bladder cancer, durvalumab, immune checkpoint inhibitor, immunotherapy, nivolumab, pembrolizumab, transitional cell carcinoma, urothelial carcinoma.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Hussain, S. A., Birtle, A., Crabb, S., Huddart, R., Small, D., Summerhayes, M., Jones, R., and Protheroe, A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:European Urology Oncology
Publisher:Elsevier
ISSN:2588-9311
ISSN (Online):2588-9311
Published Online:02 July 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in European Urology Oncology 1(6):486-500
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record